<PAGE> 1
==================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
----------------------------------
FORM 10-Q
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1998.
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from:
--------------------------------
Commission file number 0 - 26476
--------------------------------
SAFESCIENCE, INC.
(Exact name of Registrant as specified in its charter.)
NEVADA 33-0231238
(State of other jurisdiction of (IRS Employer
incorporation or organization) Identification no.)
Park Square Building
31 St. James Avenue, Suite 520
Boston, Massachusetts 02116
(Address of principal executive offices, including zip code.)
(617) 621-3133
Registrant's telephone number, including area code.
Indicate by check mark whether the Registrant (1) has filed all
reports required to be filed by the Section 13 or 15(d) of the
Securities Act of 1934 during the preceding 12 months (or for such
shorter period that the Registrant was required to file such
reports), and (2) has been subject to such filing requirements for
the past 90 days.
YES [ X ] NO [ ]
The number of shares outstanding of the Registrant's Common Stock,
$.01 par value per share, at March 31, 1998 was 12,523,227 shares.
==================================================================
<PAGE> 2
SAFESCIENCE, INC.
(A Development Stage Enterprise)
INDEX Page
Part I - Financial Information
Item 1. Financial Statements
Consolidated Balance Sheets as of March 31, 1998
and December 31, 1997 (Unaudited) 3
Consolidated Statements of Operations
for the Three Months Ended March 31, 1998 and 1997,
and the Period From December 8, 1992 (Inception) Through
March 31, 1998 (Unaudited) 4
Consolidated Statements of Cash Flows
for the Three Months Ended March 31, 1998 and 1997,
and the Period From December 8, 1992 (Inception) Through
March 31, 1998 (Unaudited) 5-6
Notes to Consolidated Financial
Statements (Unaudited) 7-10
Item 2. Management's Discussion and Analysis
of Financial Condition and Results
of Operations 11-15
Exhibit Index 16
Signatures 16
<PAGE> 3 PART 1 - FINANCIAL INFORMATION
Item 1. Financial Statements
SAFESCIENCE, INC.
(A Development Stage Enterprise)
CONSOLIDATED BALANCE SHEETS
(Unaudited)
ASSETS
<TABLE>
<CAPTION>
March 31, December
1998 31, 1997
<S> <C> <C>
Current assets:
Cash and cash equivalents $2,328,287 $2,594,312
Prepaid expenses 38,843 31,680
Other 13,264 18,400
---------- ----------
Total current assets 2,380,394 2,644,392
---------- ----------
Property and equipment, net
of accumulated depreciation 58,822 47,646
---------- ----------
Other assets:
Notes receivable - stockholders 88,948 89,233
Deposits 1,328 6,328
Restricted cash 119,138 119,138
---------- ----------
Total other assets 209,414 214,699
---------- ----------
$2,648,630 $2,906,737
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 118,547 $ 148,854
Accrued liabilities 241,433 304,763
Deferred revenue 19,975 10,000
---------- ----------
Total current liabilities 379,955 463,617
---------- ----------
Stockholders' equity:
Preferred stock, $.01 par value, 5,000,000
shares authorized; no shares issued
and outstanding - -
Common stock, $.01 par value, 25,000,000
shares authorized; 12,523,227 shares,
and 12,098,576 shares issued and
outstanding at March 31, 1998,
and December 31, 1997, respectively 125,232 120,986
Additional paid-in capital 11,522,473 10,239,018
Deficit accumulated during
development stage (9,379,030) (7,916,884)
---------- ----------
Total stockholders' equity 2,268,675 2,443,120
---------- ----------
$2,648,630 $2,906,737
========== ==========
</TABLE>
The consolidated balance sheet at December 31, 1997 has been
derived from the audited financial statements at that date.
The accompanying notes are an integral part of
these consolidated financial statements.
<PAGE> 4
SAFESCIENCE, INC.
(A Development Stage Enterprise)
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Period from
December 8,
1992
(Inception)
through
Three Months Ended March 31, March 31,
1998 1997 1998
<S> <C> <C> <C>
Revenues $ - $ - $ -
General and administrative expenses 927,512 393,148 5,158,568
Research and development costs 565,047 368,183 4,218,278
------------ ------------ ------------
Operating loss (1,492,559) (761,331) (9,376,846)
------------ ------------ ------------
Other income (expense):
Interest expense - - (139,712)
Interest income 30,413 15,444 139,295
Loss on disposal of assets - - (1,767)
------------ ------------ ------------
Total other income (expense) 30,413 15,444 (2,184)
------------ ------------ ------------
Net loss $ (1,462,146) $ (745,887) $ (9,379,030)
============ ============ ============
Basic and diluted net loss
per common share $ (0.12) $ (0.07)
============ ============
Weighted average number of common
shares outstanding 12,357,404 10,173,924
============ ============
</TABLE>
The accompanying notes are integral part of
these consolidated financial statements.
<PAGE> 5
SAFESCIENCE, INC.
(A Development Stage Enterprise)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Period from
December 8,
1992
(Inception)
through
Three Months Ended March 31, March 31,
1998 1997 1998
<S> <C> <C> <C>
Cash flows from operating activities
Net loss $(1,462,146) $ (745,887) $ (9,379,030)
Adjustments to reconcile net loss to net cash
used in operating activities:
Operating expenses paid in common
stock and options 579,701 60,000 2,520,761
Issuance of stock for
minority interest - - 719,142
Depreciation and amortization 4,571 3,066 71,257
Loss on disposal of assets - - 1,767
----------- ---------- ------------
Cash used in operating
activities before changes in
assets and liabilities (877,874) (682,821) (6,066,103)
Changes in assets and liabilities:
(Increase) decrease in:
Prepaid expenses (7,163) (22,155) (38,843)
Other assets 5,136 1,246 (12,003)
Increase (decrease) in:
Accounts payable (30,307) 105,734 118,547
Accrued liabilities (63,330) - 241,433
Deferred revenue 9,975 - 19,975
----------- ---------- ------------
Net cash used in
operating activities (963,563) (597,996) (5,736,994)
----------- ---------- ------------
Cash flows from investing activities:
Purchase of equipment (15,747) (12,080) (98,151)
Loans to stockholders - (65,000) (130,000)
Repayment of stockholders' loans 285 - 41,052
Deposits paid, net 5,000 - (1,328)
Net cash used in acquisition - - (3,822)
Increase in restricted cash - - (119,138)
----------- ---------- ------------
Net cash used in
investing activities (10,462) (77,080) (311,387)
----------- ---------- ------------
</TABLE>
The accompanying notes are an integral part of these
consolidated financial statements.
<PAGE> 6
SAFESCIENCE, INC.
(A Development Stage Enterprise)
CONSOLIDATED STATEMENTS OF CASH FLOWS continued
(Unaudited)
<TABLE>
<CAPTION>
Period from
December 8,
1992
(Inception)
through
Three Months Ended March 31, March 31,
1998 1997 1998
<S> <C> <C> <C>
Cash flows from financing activities:
Short-term borrowing $ - $ - $ 398,000
Payments on short-
term borrowing - - (90,000)
Proceeds from issuance
of common stock 708,000 2,165,000 8,099,036
Capital contributed by
stockholders - - 1,329
Debt issuance costs - - (31,697)
----------- ----------- -----------
Net cash provided by
financing activities 708,000 2,165,000 8,376,668
----------- ----------- -----------
Net increase (decrease) in cash
and cash equivalents (266,025) 1,489,924 2,328,287
Cash and cash equivalents,
beginning balance 2,594,312 444,661 -
----------- ----------- -----------
Cash and cash equivalents,
ending balance $ 2,328,287 $ 1,934,585 $ 2,328,287
=========== =========== ===========
Supplemental disclosure of
non-cash financing activities
Conversion of notes
payable into equity $ - $ - $ 310,000
=========== =========== ===========
Supplemental disclosure of
cash flow information
Cash paid for interest $ - $ - $ 5,742
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these
consolidated financial statements.
<PAGE> 7
SAFESCIENCE, INC.
(A Development Stage Enterprise)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Three Months Ended March 31, 1998 and 1997
and the Period from December 8, 1992 (Inception)
Through March 31, 1998
1. BASIS OF PRESENTATION
The Company is a development stage enterprise formed for the
research and development of pharmaceutical and agricultural
products based on carbohydrate chemistry.
The accompanying unaudited financial statements of the Company
have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission ("SEC"), and, in the opinion
of management, reflect all adjustments (consisting of only normal
recurring adjustments) necessary to present fairly the financial
position, results of operations and cash flows for the periods
presented.
Certain information and footnote disclosures included in
financial statements prepared in accordance with generally
accepted accounting principles have been omitted. These
financial statements should be read in conjunction with the
audited financial statements and notes thereto included in the
financial statements filed as part of the Company's Annual Report
on Form 10-K filed for the year ended December 31, 1997.
The results of the operations for the three months ended March
31, 1998 are not necessarily indicative of the operating results
to be expected for the full year.
2. NET LOSS PER SHARE
In December 1997, the Company adopted Statement of Financial
Accounting Standards Statement (SFAS) No. 128, Earnings per
Share. Basic loss per share is computed using the weighted
average number of common shares outstanding. Diluted net loss
per share is the same as basic net loss per share as the
inclusion of options and warrants would be antidilutive.
3. RECLASSIFICATION
Certain items in the 1997 financial statements have been
reclassified to conform with their 1998 presentation.
<PAGE> 8
SAFESCIENCE, INC.
(A Development Stage Enterprise)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Three Months Ended March 31, 1998 and 1997
and the Period from December 8, 1992 (Inception)
Through March 31, 1998
4. STOCKHOLDERS' EQUITY
Private Placement Offerings
In March 1998, the Company completed a private placement
offering of common stock. During the period January 1, 1998
through March 31, 1998 the Company sold 69,333 shares at $3.00.
The Company had sold 533,867 shares at $3.00 as of December 31,
1997. These shares include an attached warrant to purchase one
share of common stock for $4.75 for every four shares purchased.
As of March 31, 1998, warrants to purchase 150,800 shares of
common stock were outstanding from these sales.
In March 1998, the Company completed a sale of 181,818 shares
of common stock for $500,000. These shares also included an
attached warrant to purchase one share of common stock for $4.75
for every four shares of common stock purchased. As of March 31,
1998, warrants to purchase 45,455 shares of common stock at $4.75
per share were outstanding.
Warrants and Options
The Company has entered into agreements with various employees
and consultants for the grant of stock options, warrants and
shares of common stock at $.01 per share. During the three month
period ended March 31, 1998, the Company granted options to
purchase 10,555 shares of common stock and 173,500 shares of
common stock and recorded charges to operations of approximately
$580,000 relating to these grants. The charge to operations
represents the fair market value of the underlying common stock
or option on the grant date.
<PAGE> 9 SAFESCIENCE, INC.
(A Development Stage Enterprise)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Three Months Ended March 31, 1998 and 1997
and the Period from December 8, 1992 (Inception)
Through March 31, 1998
5. OTHER MATTERS . . . continued
Going Concern
The consolidated financial statements of the Company have been
prepared on a going-concern basis. That basis of accounting
contemplates the realization of assets and satisfaction of
liabilities in the normal course of conducting business
operations. As shown in the consolidated financial statements,
operations for the year ended December 31, 1997 resulted in a net
loss of $4,734,475, and as of that date the Company had a
stockholders' equity of $2,443,120. During the three months
ended March 31, 1998, the Company's net loss was $1,462,147. The
Company's ability to operate as a going concern is dependent on
its ability to continue to obtain additional capital or adequate
financing to fund successive phases of human clinical testing of
its products in order to prove their efficacy and marketability,
and to achieve a level of sales adequate to support its
operations. No adjustments have been made to the financial
statements as a result of this uncertainty.
The Company is currently engaged in raising additional capital
from qualified investors. The Company is making presentations to
various venture capital sources to raise additional capital. The
Company is also pursuing possible strategic partnerships or
collaborations with other companies interested in its substances
under development. During the quarter ending March 31, 1998, the
Company raised $708,000 through the sale of common stock and
warrants to purchase common stock.
Legal Proceedings
In March 1998, the Company settled a lawsuit with a former
consultant. The settlement agreed upon was as follows: mutual
releases were exchanged; no liability was admitted by either
party; the Company agreed to pay $25,000 in cash; and the Company
agreed to issue a number of shares of common stock which comprise
an aggregate market value of $91,250. Such stock may be issued
in one or more installments, at the Company's option and at such
times during a 90 day period following the date of settlement as
may be determined by the Company; provided that all shares will
be valued as of the close of business on the day prior to that on
which they are issued; and also provided that the Company is
required to issue at least $15,000 worth of shares during the
first thirty-day period following the settlement, and $5,000
worth of shares during the next two-week period, and $20,000
worth of shares during the succeeding two weeks, until all the
shares have been issued. As of March 31, 1998, the Company had
paid the $25,000 and accrued the remaining liability.
<PAGE> 10
SAFESCIENCE, INC.
(A Development Stage Enterprise)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Three Months Ended March 31, 1998 and 1997
and the Period from December 8, 1992 (Inception)
Through March 31, 1998
5. OTHER MATTERS . . . continued
Licensing Agreements
In October 1997, the Company announced that AGI had entered
into an agreement with an Israeli biotechnology company, Leket-
Bar, Ltd., to acquire a worldwide, exclusive license to all
Leket-Bar's products. On March 6, 1998 Leket-Bar and the Company
amended the payment terms of the licensing agreement.
Originally, the Company was to pay Leket-Bar $25,000 per quarter
over a four year period. Under the amended terms of the
agreement, the Company is obligated to pay $225,000 in 1998,
$100,000 in 1999, and $50,000 in the year 2000.
<PAGE> 11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with
the consolidated financial statements and the notes thereto:
Overview
SafeScience, Inc. (formerly IGG International, Inc.) is
developing and marketing a portfolio of agricultural home and
garden products and pharmaceutical products under the brand
SafeScience(R)' as an alternative to conventional treatments
employing potentially harmful chemicals. Beyond the Company's
agricultural products, its human therapeutic products include a
carbohydrate compound to treat cancer, which is in human clinical
trials, as well as an antifungal compound. The Company has not
generated any revenue related to these products through March 31,
1998. The Company operates through its two wholly owned
subsidiaries: its agricultural subsidiary, Agricultural
Glycosystems, Inc. (AGI), and its human therapeutics subsidiary,
International Gene Group, Inc. (IGGI).
The Company is presently researching several products, nearly
all of which are derived from naturally occurring substances:
AGI's principal products are Greenleaf Plant Defense Booster
("Greenleaf PDB," formerly ELEXA), an inhibitor of plant fungus
(which was recently granted approval by the Environmental
Protection Agency ("EPA")); SAF-711, a second fungicide product
derived from natural carbohydrates extracted from a plant ("SAF-
711"); and Dentamet, a third fungicide which has the potential of
working as a fumigant; and a line of non-toxic fertilizer
products. IGGI's principal products are GBC 590, a natural
complex carbohydrate glycoprotein which inhibits human melanoma
cancer cells; CAN-296, a natural antifungal agent which inhibits
infections such as Candida, and a Microorganism Substance MMS-1.
Patents for MMS-1, Dentamet and certain fertilizers have been
issued and all other patents are currently pending for all
products.
In October 1997, the Company announced that AGI had entered
into an agreement with an Israeli biotechnology company, Leket-
Bar Ltd., to acquire a worldwide, exclusive license to all Leket-
Bar's products. These products consist of a series of patented
products, including several modified carbohydrate compounds for
use as fertilizers and fungicides. The products acquired in this
transaction have been approved and marketed in Israel and other
countries. Several of the products acquired are carbohydrate-
based fertilizers which do not require registration with the EPA
to be sold in the United States.
<PAGE> 12
In April 1997, the Company announced that AGI had entered into
an exclusive, worldwide licensing agreement with Agrogene, Ltd.,
an Israeli-based biotechnology company specializing in products
for agriculture. AGI acquired the rights to commercialize the
compounds derived from a collection of natural carbohydrates
identified and patented by Agrogene. The first compound which is
under development, a fungicide known as SAF-711, has shown in
field and greenhouse studies an ability to kill a broad range of
fungi on plants such as downy mildews, late blight, powdery
mildews and rusts.
In December 1997, the Company entered into two agreements for
the distribution of the Company's agricultural products. The
first agreement provides for exclusive distribution rights in the
United Arab Emirates, the Sultanate of Oman, Bahrain, Qatar and
the Kingdom of Saudi Arabia. The second agreement provides for
exclusive distribution rights in New Zealand and Australia. At
the time of signing the agreements, the Company received payments
of $10,000 from each distributor, to be credited toward amounts
subsequently payable under the agreements. In addition, in
March, 1998 the Company entered into another agreement providing
for exclusive distribution rights in Argentina and Uruguay. No
advance payment was received in connection with such agreement.
The Company has also acquired the trademark rights to the name
"Greenleaf," which is the brand name that the Company has begun
using to market its non-toxic products, including the products
acquired from Leket-Bar. Greenleaf is a registered United States
trademark.
On April 24, 1998, the Company entered into an agreement with
Dominion BioSciences, Inc. that gives SafeScience the exclusive
marketing rights for the worldwide retail consumer distribution
of certain patented products developed and manufactured by
Dominion BioSciences, Inc. for the control of cockroaches and
other household insect pests. Under the terms of the agreement,
both companies will combine research efforts to create worldwide
non-toxic consumer products for pest control that will be
marketed under the double brands, SafeScience(R) and Ecologix(TM)
(trademark of Dominion).
On May 1, 1998, the Company signed an agreement with MIGAL
Galilee Technology Center (MIGAL) in Kiryat Shmona, Israel
whereby MIGAL will act as a partner in developing new products
that will be commercialized under the world brand,
SafeScience(R).
MIGAL is a scientific institute established in 1979. It is
dedicated to research and development in the area of agricultural
and environmental biotechnology, including plant, pathogens, and
human genetics. R&D activities include development of improved
crops, virology, recombinant vaccine for human and animals,
<PAGE> 13
immunology, molecular biology. Other applied research activities
include aquaculture for nutrition and control of reproduction,
production of fungal enzymes, biodegradation of toxic compounds,
soil and water microbiology for bioremediation of pollution,
composting urban and agricultural wastes and anaerobic digestion
of animal and industrial wastes. MIGAL employs 25 researchers of
Ph.D. level and above in a staff of over 100 researchers,
engineers, technicians, and students for higher degrees.
Details of the agreement include the co-development of certain
projects currently underway at MIGAL and also to develop new
products and technologies for SafeScience(R). The agreement also
allows MIGAL to identify itself as a SafeScience(R) Institute and
gives SafeScience the option to purchase an equity stake in
MIGAL.
On May 4, 1998, the Company announced that its Common Stock
began trading on the NASDAQ Small Cap Market under its current
ticker symbol SAFS.
Potential risks associated with the development of the
Company's products are: 1) some of the products referred to
herein may never be developed; 2) anticipated future losses due
to the cost of research and development; 3) the timing and cost
associated with governmental regulation and approval; 4) absence
of patent protection; 5) the risk of product liability claims;
and 6) the uncertainty that the Company will ever operate
profitably. For all of the foregoing reasons, an investment in
the Company's securities is risky and purchasers should be aware
that they might lose their entire investment.
Prior to marketing certain of its products, the Company must
obtain regulatory approval from the United States Food and Drug
Administration ("FDA") and/or the EPA. The Company announced on
November 6, 1997, that it had received EPA approval of Greenleaf
PDB.
The Company has financed itself by a series of private
placement financing. In the Company's estimation these financing
have sufficiently funded the Company to continue its product
development agenda, pursue regulatory approvals of products and
begin to market its existing products. However, the Company has
to obtain and will continue to seek additional financing through
the private sale of restricted securities to investors, and will
consider joint venture, licensing or similar arrangements with
large companies to provide the funding necessary for additional
activities, such as commercialization of its existing products
and continued development of new products. There can be no
assurance that the Company will enter into any such arrangements,
complete its research and development, obtain additional
appropriate regulatory approvals, or develop, manufacture,
market, or distribute commercially viable products.
<PAGE> 14
To date, the Company's activities have consisted primarily of
research, development and testing. Such activities have resulted
in accumulated losses through the end of the Company's most
recent fiscal year. The Company anticipates that it will incur
substantial losses in 1998 as a result of its continued research.
Business Objective
SafeScience has embarked on a mission to build a world brand.
As a starting position, the Company has developed carbohydrate
based products in both the areas of agriculture and human
therapeutics. The Company will market and distribute the
SafeScience "Greenleaf" brand of agricultural products in 1998.
In addition, new products and technologies will be developed that
will bolster "SafeScience, Inc." as a world standard for product
safety.
Results of Operations: March 31, 1998 versus March 31, 1997
As a development stage enterprise from the date of its inception,
the Company has not commenced production of any products nor
derived any product sales or net income. The Company intends to
begin production of its products in the second quarter of 1998.
The Company's business activities through March 31, 1998 have
consisted principally of research, product development and
testing and the acquisition and funding of capital to sustain
business activities.
General and administrative expenses increased from $393,148
for the three months ended March 31, 1997 to $927,512 for the
three months ended March 31, 1998, an increase of $534,364 or
136%. This increase was attributable to an overall increase in
business activities during the quarter including an increase in
business development salaries, including approximately $494,000
resulting from the grant and exercise of options to purchase
common stock.
Research and development costs for consultants, supplies and
testing increased from $368,183 for the three months ended March
31, 1997 to $565,047 for the three months ended March 31, 1998,
an increase of $196,864 or 53.5%. This increase was principally
attributable to a combination of increasing and expanding
research efforts on complex carbohydrate and micro-organism
substances, conducted on both subcontracted and collaboration
bases, initial research and testing costs for new processes or
development products introduced during 1997 and costs associated
with recent licensing agreements. Included in research and
development costs is approximately $86,000 resulting from the
issuance of stock grants, and stock options and warrants to
purchase common stock.
<PAGE> 15
Interest income increased from $15,444 for the three months
ended March 31, 1997 to $30,413 for the three months ended March
31, 1998, an increase of $14,969. This increase was attributable
to the temporary investment of cash proceeds received from
private placements of the company's securities during 1997 and
1998.
Liquidity and Capital Resources
Since inception, the Company has funded its operations
primarily with the proceeds from debt and equity securities
totaling approximately $8,400,000. For the quarter ended March
31, 1998, the Company's operations utilized cash of $963,563
primarily to fund the operating loss. This use of cash was
offset by equity financings that resulted in net proceeds of
$708,000 to the Company.
The Company's audited financial statements for the year ended
December 31, 1997 indicated that there was an uncertainty as to
the Company's ability to continue as a going concern. As of
March 31, 1998, the Company's accumulated deficit is $9,379,030
and cash balances are $2,328,287. The Company has no bank lines
of credit or other commercial financing sources at present and
does not expect to obtain any. It is not known whether
additional funds could be borrowed from stockholders or other
sources.
The Company's future is dependent upon its ability to obtain
financing to fund its operations. The Company expects to incur
substantial additional operating costs, including costs related
to ongoing research and development activities, preclinical
studies and clinical trials. The Company believes that its
existing funds will be sufficient to fund its operating expenses
and capital requirements as currently planned through late-1998.
The Company is currently seeking to complete a private equity
placement. There can be no assurance that the Company will be
able to obtain the additional funding that it will require on
acceptable terms, if at all.
Inflation and Changing Prices
To date, the impacts of inflation and changing prices on the
Company's operations have been minimal. The Company is currently
testing its processes and products in the United States and
Israel in accordance with royalty and research agreements that
are already in effect. During the research, development and
testing phases of operations to satisfy regulatory requirements
for the products under development, the Company expects
inflationary pressures in both countries will be minimal and,
hence, not have a material impact on operations.
<PAGE> 16
EXHIBIT INDEX
Item 6. Exhibits.
Number Description
27 Financial Data Schedule
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated this 14th day of May.
SAFESCIENCE, INC.
(the "Registrant")
BY: /s/ Bradley J. Carver,
President, Treasurer, Chief
Financial Officer and a member
of the Board of Directors
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Statement of Financial Condition at March 31, 1998 (Unaudited) and the
Statement of Operations for the three months ended March 31, 1998
(Unaudited) and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-END> MAR-31-1998
<CASH> 2,328,287
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 2,380,394
<PP&E> 95,312
<DEPRECIATION> 36,490
<TOTAL-ASSETS> 2,648,630
<CURRENT-LIABILITIES> 379,955
<BONDS> 0
0
0
<COMMON> 125,232
<OTHER-SE> 2,143,443
<TOTAL-LIABILITY-AND-EQUITY> 2,648,630
<SALES> 0
<TOTAL-REVENUES> 30,413
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 1,492,559
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (1,462,146)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,462,146)
<EPS-PRIMARY> (0.12)
<EPS-DILUTED> (0.12)
</TABLE>
